Idogen – Introduction to the share
Tuesday June 29th you can meet and ask questions directly to Idogen CEO Anders Karlsson when he gives an introduction to the Idogen share.
Idogen was founded in 2009 and is a Swedish biotech company locacted in Lund, Sweden. Idogen is listed on the First North Growth Market and with a market cap 62 mio. SEK. Idogen develops tolerogenic cell therapies to prevent the patient’s immune system from attacking biological agents, transplanted organs or the body’s own cells or tissues.